Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

키워드

참고문헌 (13)

1. Lok ASF, "Toward a functional cure for hepatitis B", Gut Liver, 18, pp.593~601 (2024)
2. Zhang X, "Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors", ACS Infect Dis, 5, pp.759~768 (2019)
3. Yuen MF, "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients", Clin Mol Hepatol, 30, pp.375~387 (2024)
4. Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
5. Yuen MF, "Long-term open-label vebicorvir for chronic HBV infection : Safety and off-treatment responses", JHEP Rep, 6, pp.100999~ (2024)
6. Volz T, "Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients", Gastroenterology, 133, pp.843~852 (2007)
7. Jang JW, "Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance", Clin Mol Hepatol, 27, pp.207~218 (2021)
8. Mason WS, "HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998 (2016)
9. Chow N, "Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion", Clin Infect Dis, 76, pp.e801~e809 (2023)
10. Berke JM, "Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379", Antimicrob Agents Chemother, 64, pp.e02439-19~ (2020)
11. Wu D, "The potential immune regulation benefit of CpAMs beyond HBV suppression", Lancet Gastroenterol Hepatol, 6, pp.680~682 (2021)
12. Sulkowski MS, "Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.1265~1275 (2022)
13. Yuen MF, "Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.642~652 (2022)

관련 논문AI추천